You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

MAB 124I-omburtamab

Showing 1 - 25 of 306
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

DIPG Trial (131I-Omburtamab, Convention Enhanced Delivery)

Not yet recruiting
  • DIPG
  • (no location specified)
Feb 7, 2022

Renal Cancer Trial in New York (124IcG250)

Active, not recruiting
  • Renal Cancer
  • New York, New York
    Memorial Sloan Kettering Cancer Center
May 4, 2022

Renal Cell Carcinoma (RCC) Trial in Heidelberg (Chimeric mAb cG250, Sunitinib malate)

Terminated
Has Results
  • Renal Cell Carcinoma (RCC)
  • Chimeric monoclonal antibody cG250
  • Sunitinib malate
  • Heidelberg, Victoria, Australia
    Austin Health (Ludwig Institute Oncology Unit)
Oct 3, 2022

CNS/Leptomeningeal Tumors Trial in New York (131I-omburtamab)

Available
  • Central Nervous System/Leptomeningeal Neoplasms
  • New York, New York
    Memorial Sloan Kettering Cancer Center
Jul 15, 2022

Leptomeningeal Metastasis, Solid Tumor, Adult Trial in United Kingdom, United States (radiolabeled DPTA-omburtamab)

Withdrawn
  • Leptomeningeal Metastasis
  • Solid Tumor, Adult
  • radiolabeled DPTA-omburtamab
  • Los Angeles, California
  • +7 more
Jul 12, 2022

Medulloblastoma, Childhood Trial in Worldwide (177Lu-DTPA-omburtamab)

Terminated
  • Medulloblastoma, Childhood
  • Rochester, Minnesota
  • +9 more
Aug 15, 2022

Transthyretin Amyloidosis Trial in New York (I 124-Evuzamitide)

Recruiting
  • Transthyretin Amyloidosis
  • I 124-Evuzamitide
  • New York, New York
    Columbia University Irving Medical Center
Nov 23, 2022

Rabies Virus Infection Trial in Kunming (Natural full human mAb CBB 1 injection, Rabies Human Immunoglobulin (HRIG), Natural

Not yet recruiting
  • Rabies Virus Infection
  • Natural full human monoclonal antibody CBB 1 injection
  • +3 more
  • Kunming, Yunnan, China
    The First Affiliated Hospital of Yunnan University of Traditiona
Apr 14, 2023

Systemic Amyloidosis Trial in Knoxville (Injection of peptide p5+14 radiolabeled with iodine-124 (124I-AT-01))

Active, not recruiting
  • Systemic Amyloidosis
  • Injection of peptide p5+14 radiolabeled with iodine-124 (124I-AT-01)
  • Knoxville, Tennessee
    University of Tennessee Graduate School of Medicine
Jul 28, 2023

Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) Trial in Pittsburgh (Pembrolizumab, Carboplatin,

Not yet recruiting
  • Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)
  • Pittsburgh, Pennsylvania
    UPMC Hillman Cancer Center
Sep 18, 2023

Healthy Volunteers Trial in Philadelphia (dMAb AZD5396, dMAb AZD8076, Electroporation device)

Recruiting
  • Healthy Volunteers
  • dMAb AZD5396
  • +4 more
  • Philadelphia, Pennsylvania
    University of Pennsylvania
Nov 16, 2022

Nasopharyngeal Carcinoma Trial in Guangzhou (Camrelizumab, Gemcitabine, Cisplatin)

Recruiting
  • Nasopharyngeal Carcinoma
  • Guangzhou, Guangdong, China
    Department of Nasopharyngeal Carcinoma, Sun Yat-sen University C
May 3, 2023

Solid Tumor Trial (18F-FDG)

Not yet recruiting
  • Solid Tumor
  • (no location specified)
Jul 18, 2022

Amyloidosis, Transthyretin Amyloidosis Trial in Portland (124I-Evuzamitide)

Recruiting
  • Amyloidosis
  • Transthyretin Amyloidosis
  • 124I-Evuzamitide
  • Portland, Oregon
    Oregon Health & Science University
Feb 24, 2023

Anti-CGRP Monoclonal Antibody Response After Switching (AMARAS)

Recruiting
  • Migraine
  • Head Pain
    • Valladolid, Spain
      Hospital Clínico Universitario de Valladolid
    Mar 23, 2023

    Colorectal Tumors, Colorectal Cancer, Colorectal Tumor Trial in New York (Iodine-124 labeled humanized A33 (antibody))

    Active, not recruiting
    • Colorectal Neoplasms
    • +3 more
    • Iodine-124 labeled humanized A33 (antibody)
    • New York, New York
      Memorial Sloan Kettering Cancer Center
    Apr 26, 2022

    Lymphoma Trial (BYON4228 + Rituximab)

    Not yet recruiting
    • Lymphoma
    • BYON4228 + Rituximab
    • (no location specified)
    Feb 20, 2023

    Novel Monoclonal Antibodies in B-cell Non-Hodgkin Lymphoma in

    Not yet recruiting
    • Non-Hodgkin Lymphoma, B-cell
    • "novel" MAB (alone or in combination)
    • Viagrande, Catania, Italy
    • +57 more
    Aug 18, 2023

    Gastrointestinal Cancer Trial in Beijing (124I-18B10(10L) PET/CT)

    Recruiting
    • Gastrointestinal Cancer
    • 124I-18B10(10L) PET/CT
    • Beijing, China
      HUA ZHU
    Jul 18, 2022

    Neuroblastoma, CNS Metastases, Leptomeningeal Metastases Trial in Worldwide (131I-omburtamab)

    Recruiting
    • Neuroblastoma
    • +2 more
    • 131I-omburtamab
    • Los Angeles, California
    • +11 more
    Dec 17, 2021

    Tetanus Trial in China (TNM002, Human tetanus immunoglobulin (HTIG))

    Recruiting
    • Tetanus
    • TNM002
    • Human tetanus immunoglobulin (HTIG)
    • Hefei, Anhui, China
    • +29 more
    Jan 19, 2023

    Pyoderma, Pyoderma Gangrenosum, Pyoderma Vegetans Trial in Minsk, Riga (Monoclonal antibody (Mab) sB24M)

    Active, not recruiting
    • Pyoderma
    • +3 more
    • Monoclonal antibody (Mab) sB24M
    • Minsk, Belarus
    • +1 more
    Jul 8, 2022

    Advanced or Metastatic Solid Tumors Trial (DCSZ11)

    Not yet recruiting
    • Advanced or Metastatic Solid Tumors
    • (no location specified)
    Mar 14, 2023

    Neuroblastoma, Ganglioneuroblastoma Trial in Moscow (monoclonal antibodies GD2)

    Recruiting
    • Neuroblastoma
    • Ganglioneuroblastoma
    • monoclonal antibodies GD2
    • Moscow, Russian Federation
      Research Institute of Pediatric Hematology, Oncology and Immunol
    Oct 4, 2023

    Plasmodium Falciparum Infection, Malaria Trial in Faladje, Kalifabougou, Torodo (L9LS (VRC-MALMAB0114-00-AB), Normal Saline)

    Not yet recruiting
    • Plasmodium Falciparum Infection
    • Malaria
    • L9LS (VRC-MALMAB0114-00-AB)
    • Normal Saline
    • Faladje, Région De Koulikoro, Mali
    • +2 more
    Apr 17, 2023